dc.creator | Thomas K., Lazarini A., Kaltsonoudis E., Drosos A., Papalopoulos I., Sidiropoulos P., Katsimbri P., Boumpas D., Tsatsani P., Gazi S., Fragkiadaki K., Tektonidou M., Sfikakis P.P., Pantazi L., Boki K.A., Grika E.P., Vlachoyiannopoulos P.G., Karagianni K., Sakkas L.I., Dimitroulas T., Garyfallos A., Kassimos D., Evangelatos G., Iliopoulos A., Areti M., Georganas C., Melissaropoulos K., Georgiou P., Vounotrypidis P., Ntelis K., Mavragani C.P., Bournazos I., Katsifis G., Mavrommatis C., Kitas G.D., Vassilopoulos D. | en |
dc.date.accessioned | 2023-01-31T10:08:26Z | |
dc.date.available | 2023-01-31T10:08:26Z | |
dc.date.issued | 2018 | |
dc.identifier | 10.31138/mjr.29.1.27 | |
dc.identifier.issn | 24593516 | |
dc.identifier.uri | http://hdl.handle.net/11615/79705 | |
dc.description.abstract | Aim of the study: To evaluate the current disease characteristics, treatment and comorbidities of rheumatoid arthritis (RA) in Greece. Methods: Multicenter, cross-sectional study with a 9-month recruitment period between 2015 and 2016. Demographics, disease characteristics, treatment and comorbidities were collected via a web-based platform. Results:2.491 RA patients were recruited: 96% from tertiary referral centers, 79% were females with a mean age of 63.1 years and disease duration of 9.9 years. Fifty-two percent were rheumatoid factor and/or anti-CCP positive, while 41% had erosive disease. Regarding treatment, 82% were on conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), 42% on biologic DMARDs (TNFi: 22%, non-TNFi: 20%) and 40% on corticosteroids (mean daily dose: 5.2 mg). Despite therapy, 36% of patients had moderate and 12% high disease activity. The most frequent comorbidities were hypertension (42%), hyperlipidemia (33%), osteoporosis (29%), diabetes mellitus (15%) and depression (12%). Latent tuberculosis infection (positive tuberculin skin test or interferon gamma release assay) was diagnosed in 13 and 15.3% of patients, respectively. Regarding chronic viral infections, 6.2% had history of herpes zoster while 2% and 0.7% had chronic hepatitis B and C virus infection, respectively. A history of serious infection was documented in 9.6%. Only 36% and 52% of the participants had ever been vaccinated against pneumococcus and influenza virus, respectively. Conclusion: This is one of the largest epidemiologic studies providing valuable data regarding the current RA characteristics in Greece. Half of patients were seropositive but despite therapy, half displayed residual disease activity, while preventive vaccination was limited. © Thomas K, Lazarini A, Kaltsonoudis E, Drosos AA, Papalopoulos I, Sidiropoulos P, Katsimbri P, Boumpas D, Tsatsani P, Gazi S, Fragkiadaki K, Tektonidou M, Sfikakis P P, Pantazi L, Boki K A, Grika E P, Vlachoyiannopoulos P G, Karagianni K, Sakkas L I, Dimitroulas T, Garyfallos A, Kassimos D, Gerasimos E, Iliopoulos A, Areti A, Georganas C, Melissaropoulos K, Georgiou P, Vounotrypidis P, Ntelis K, Mavragani C P, Bournazos I, Katsifis G, Mavrommatis C, Kitas G D, Vassilopoulos D. | en |
dc.language.iso | en | en |
dc.source | Mediterranean Journal of Rheumatology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085377516&doi=10.31138%2fmjr.29.1.27&partnerID=40&md5=a1abf83224043825829891215a829eca | |
dc.subject | analgesic agent | en |
dc.subject | disease modifying antirheumatic drug | en |
dc.subject | rheumatoid factor | en |
dc.subject | tumor necrosis factor inhibitor | en |
dc.subject | adult | en |
dc.subject | Article | en |
dc.subject | chronic hepatitis B | en |
dc.subject | chronic hepatitis C | en |
dc.subject | clinical evaluation | en |
dc.subject | clinical feature | en |
dc.subject | cohort analysis | en |
dc.subject | comorbidity assessment | en |
dc.subject | cross-sectional study | en |
dc.subject | depression | en |
dc.subject | diabetes mellitus | en |
dc.subject | disease activity | en |
dc.subject | disease duration | en |
dc.subject | female | en |
dc.subject | Greece | en |
dc.subject | herpes zoster | en |
dc.subject | human | en |
dc.subject | hyperlipidemia | en |
dc.subject | hypertension | en |
dc.subject | interferon gamma release assay | en |
dc.subject | lung tuberculosis | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | middle aged | en |
dc.subject | multicenter study | en |
dc.subject | osteoporosis | en |
dc.subject | Parainfluenza virus infection | en |
dc.subject | phase 1 clinical trial | en |
dc.subject | phase 2 clinical trial | en |
dc.subject | phase 3 clinical trial | en |
dc.subject | pneumococcal infection | en |
dc.subject | prospective study | en |
dc.subject | rheumatoid arthritis | en |
dc.subject | tertiary care center | en |
dc.subject | treatment duration | en |
dc.subject | treatment outcome | en |
dc.subject | tuberculin test | en |
dc.subject | vaccination coverage | en |
dc.subject | virus infection | en |
dc.subject | Greek Rheumatology Society and Professional Association of Rheumatologists | en |
dc.title | Multicenter cross-sectional study of patients with rheumatoid arthritis in Greece: Results from a cohort of 2.491 patients | en |
dc.type | journalArticle | en |